Older patients and immune checkpoint inhibitors: a case report of good tolerance and complete response in an octogenarian man with metastatic urothelial carcinoma
V. Martelli, R. Borea, A. Damassi, S.E. Rebuzzi, V. Murianni, F. Catalano, G. Fornarini
Vol.6 (2021), issue 1, pag. 15 - 22
| Received | 25/01/2021 |
| Accepted | 12/02/2021 |
| Published | 12/03/2021 |
| Review by | Single-blind |
| DOI | https://doi.org/10.48253/AGO5 |
ABSTRACT
Abstract
The introduction of immune checkpoint inhibitor therapies has dee- ply modified the management landscape of advanced solid tumors, including urothelial carcinoma, for which platinum-based chemothe- rapy represented the cornerstone in the past 30 years.
Despite long last efficacy and good toxicity profiles, their safety is far to be completely understood in those groups underrepresen- ted in clinical trials, such as the elderly one. Older patients are an intriguing challenge for clinical oncologists, due to a higher rate of comorbidity and lower functional reserve, which can lead to an in- creased incidence of ICI adverse events. However, there’s a lack of data from the real world, about the issue.
In this case report, we describe an octogenarian man treated with anti-PD-L1immune checkpoint inhibitor Atezolizumab, with good adherence to the therapy and great disease response, suggesting efficacy and safety of this kind of treatment even in the elderly po- pulation.
KEYWORDS
Immunotherapy, immune checkpoint inhibitor, elderly, safety, toxicity, older-old, urothelial carcinoma, atezolizumab, octogenarian.